11:I[8479,["349","static/chunks/349-c9bb88602114b6df.js","173","static/chunks/173-8ffc04d433c3339f.js","865","static/chunks/865-f26eeb7d8a4ff1d6.js","444","static/chunks/app/episode/%5Buuid%5D/page-e9df19c6dc9fc3dd.js"],"EpisodeClient"] 12:T443,The Food and Drug Administration has issued emergency use authorizations for two monoclonal antibody treatments for COVID-19 – one produced by Eli Lilly and another by Regeneron. But emergency use authorization doesn't assure the drugs are effective.

In this episode of Short Wave, NPR's daily science podcast, science correspondent Richard Harris explains how the new treatments work — and whether they could really make a difference for patients with COVID-19.

Listen to more episodes of Short Wave on Apple Podcasts or Spotify.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy13:T443,The Food and Drug Administration has issued emergency use authorizations for two monoclonal antibody treatments for COVID-19 – one produced by Eli Lilly and another by Regeneron. But emergency use authorization doesn't assure the drugs are effective.

In this episode of Short Wave, NPR's daily science podcast, science correspondent Richard Harris explains how the new treatments work — and whether they could really make a difference for patients with COVID-19.

Listen to more episodes of Short Wave on

BONUS: How Effective Are Antibody Treatments For COVID-19?